Sunday, September 20, 2026

Canopy Growth Stock Slides By 30% In The Last 21 Sessions

Canopy Growth Stock Slides By 30% In The Last 21 Sessions

Canopy Growth Corporation (NASDAQ: CGC) is an eminent name in the ever-growing cannabis industry, with its products reaching across borders in Canada, the US, and Germany. The company specializes in the production and retail of cannabis and hemp-based goods. However, the once flourishing corporation is experiencing turmoil as its shares undergo a severe plummet, marked by a 30.78% tumble over 21 sessions ending with a sh.39 close last Friday. This dip represents a shocking 91.85% fall from their 52-week high of.77.

Increasing Competition and Legalization

The escalation of marijuana legalization globally brings forth increased competition in the cannabis market. This heightened rivalry, especially in Canopy's main areas of operation, seems to be a contributing factor to the financial hardships encountered by the corporation.

Financial Woes

Though Canopy Growth reported a trailing twelve-month earnings per share (EPS) of 5.34, its profitability metrics tell a different story. The company’s Return on Equity (ROE), a measure of the efficiency in generating profits from shareholders' equity, stood at a glaring negative of -151.11% over the same timeframe. This is indicative of its inability to yield positive shareholder investments and returns, which could also be influencing its stock price adversity.

Market Volatility

Over the past week, the company experienced an average negative intraday variation of 2.75%. Additionally, the value of its stock has depreciated substantially when viewed against its 50-day moving average of sh.70 and the 200-day moving average of.05.

Declining Revenues

Revenue growth for Canopy has declined by 27.6% year-on-year, amounting to 402.9M for the trailing 12 months in comparison with the same period last year. It suggests a scenario of stagnating sales or even worse, dwindling profitability, a situation that not only dampens its stock price but also sabotages returns for shareholders.

Investor Caution

In light of the recent drawbacks faced by Canopy Growth, investors and stakeholders should tread with caution. The company's financial performance and health are under strain, as made evident by its unstable stock price, declining revenues, and negative return on equity. These factors raise concerns about the long-term profitability and potential of Canopy Growth Corporation.

More news about Canopy Growth (CGC).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Boom Hits a Fork: Slowdown Calls Clash with Capex Confidence as Markets Get Nervous
Dario Amodei's repeated calls for a global slowdown in frontier AI development, echoed by Microsoft's new humanist AI code of conduct and FTC antitrust caution, are being publicly rejected by Nvidia and Meta leadership even as hyperscaler spending draws fresh skeptical scrutiny (Wachter's analysis, Burry-style overbuilding worries) and weak guidance from Adobe and a post-slowdown-comment selloff in GE Vernova signal investor jitters. Meanwhile wealth and security effects of the AI race keep compounding — Zhang Yiming's fortune surging on AI-driven ByteDance value, a Chinese hacking firm weaponizing AI against stolen government secrets, and low-quality AI-generated products (an AI sitcom, a spam-flooding agent platform) fueling backlash even as adoption races ahead.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Berkshire Hathaway
Both facts report Berkshire Hathaway's cash position on 2026-01-01 with identical observation timestamps, but claim vastly different values: 380 billion USD vs 400 USD. These cannot both be true for the same entity at the same point in time. The magnitude of the discrepancy (a factor of ~10^9) rules out rounding, unit conversion, or methodological differences.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,982
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,982 facts checked against source5,299 source documents archived
Query this data → isubstrate.com